SGLT2抑制剂对射血分数保留的心力衰竭的保护作用及机制研究进展
Protective Effect and Mechanism of SGLT2 Inhibitor on Heart Failure with Preserved Ejection Fraction
高棣英 1吴铿1
作者信息
- 1. 广东医科大学附属医院,广东湛江 524001
- 折叠
摘要
心力衰竭(心衰)是心血管疾病发展的终末阶段和主要死因,其患病率、再住院率、病死率均较高,防治难度极大.其中射血分数保留的心力衰竭(HFpEF)是心衰的主要类型,目前约占心衰总患病人数的50％,在65岁以上人群中超过70％.随着新型抗心衰药物的出现,射血分数降低的心力衰竭患者的再住院率和死亡率逐渐降低,但HFpEF仍面临治疗困境.据报道,钠-葡萄糖共转运蛋白2抑制剂可独立作用于心脏,并通过多种机制治疗心衰患者,但其提供临床益处的生物学机制尚未完全阐明.
Abstract
Heart failure is the terminal stage and the main cause of death in the development of cardiovascular disease,with a high prevalence rate,rehospitalization rate and mortality rate,making the prevention and treatment extremely difficult.Among them,heart failure with preserved ejection fraction(HFpEF)is the main type of heart failure,accounting for about 50％of the total number of heart failure,and more than 70％of people over 65 years old.With the emergence of new anti-heart failure drugs,the patients'rehospitalization rate and mortality rate of heart failure with reduced ejection fraction have gradually decreased,but HFpEF still faces a treatment dilemma.It has been reported that sodium-glucose co-transporter 2 inhibitor act independently on the heart,and treat heart failure patients through multiple mechanisms,but the biological mechanisms that provide clinical benefits have not been fully elucidated.
关键词
心力衰竭/射血分数保留的心力衰竭/钠-葡萄糖共转运蛋白2抑制剂Key words
Heart failure/Heart failure with preserved ejection fraction/Sodium-glucose co-transporter 2 inhibitor引用本文复制引用
出版年
2024
NETL
NSTL
万方数据